Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Chronic Obstructive Pulmonary Disorder (COPD) Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Status and Forecast (2016-2027)
      • 1.3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Chronic Obstructive Pulmonary Disorder (COPD) Supply by Company

    • 2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Sales Value by Company
    • 2.2 Chronic Obstructive Pulmonary Disorder (COPD) Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Chronic Obstructive Pulmonary Disorder (COPD) Market Status by Category

    • 3.1 Chronic Obstructive Pulmonary Disorder (COPD) Category Introduction
      • 3.1.1 Short-Acting Bronchodilators
      • 3.1.2 Corticosteroids
      • 3.1.3 Methylxanthines
      • 3.1.4 Long-Acting Bronchodilators
      • 3.1.5 Phosphodiesterase-4 Inhibitors
      • 3.1.6 Others
    • 3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Chronic Obstructive Pulmonary Disorder (COPD) Market Status by End User/Segment

    • 4.1 Chronic Obstructive Pulmonary Disorder (COPD) Segment by End User/Segment
      • 4.1.1 Hospital
      • 4.1.2 Clinic
    • 4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Status by Region

    • 5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market by Region
    • 5.2 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Status
    • 5.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Status
    • 5.4 Asia Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Status
    • 5.5 Central & South America Chronic Obstructive Pulmonary Disorder (COPD) Market Status
    • 5.6 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Status

    6 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Status

    • 6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Status

    • 7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Status

    • 8.1 Asia Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Chronic Obstructive Pulmonary Disorder (COPD) Market Status

    • 9.1 Central & South America Chronic Obstructive Pulmonary Disorder (COPD) Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Status

    • 10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Forecast by Category and by End User/Segment

    • 12.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Sales Value Forecast (2022-2027)
    • 12.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecast by Category
    • 12.3 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecast by End User/Segment

    13 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Forecast by Region/Country

    • 13.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 GSK
      • 14.1.1 Company Information
      • 14.1.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Teva Pharmaceuticals
      • 14.2.1 Company Information
      • 14.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.2.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Roche
      • 14.3.1 Company Information
      • 14.3.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.3.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Pfizer
      • 14.4.1 Company Information
      • 14.4.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.4.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Novartis
      • 14.5.1 Company Information
      • 14.5.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.5.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Merck
      • 14.6.1 Company Information
      • 14.6.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.6.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Boehringer Ingelheim
      • 14.7.1 Company Information
      • 14.7.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.7.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 AstraZeneca
      • 14.8.1 Company Information
      • 14.8.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.8.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Astellas Pharma
      • 14.9.1 Company Information
      • 14.9.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.9.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Asmacure
      • 14.10.1 Company Information
      • 14.10.2 Chronic Obstructive Pulmonary Disorder (COPD) Product Introduction
      • 14.10.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Ario Pharma
    • 14.12 Aquinox Pharmaceuticals
    • 14.13 Almirall
    • 14.14 Ache

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Chronic Obstructive Pulmonary Disorder (COPD) market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Chronic Obstructive Pulmonary Disorder (COPD) market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Short-Acting Bronchodilators
      Corticosteroids
      Methylxanthines
      Long-Acting Bronchodilators
      Phosphodiesterase-4 Inhibitors
      Others

      Segmented by End User/Segment
      Hospital
      Clinic

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      GSK
      Teva Pharmaceuticals
      Roche
      Pfizer
      Novartis
      Merck
      Boehringer Ingelheim
      AstraZeneca
      Astellas Pharma
      Asmacure
      Ario Pharma
      Aquinox Pharmaceuticals
      Almirall
      Ache
      Buy now